Rhumbline Advisers Sells 35,973 Shares of Merck & Co. (MRK)

Rhumbline Advisers cut its stake in Merck & Co. (NYSE:MRK) by 0.8% in the first quarter, HoldingsChannel reports. The institutional investor owned 4,468,429 shares of the company’s stock after selling 35,973 shares during the quarter. Rhumbline Advisers’ holdings in Merck & Co. were worth $243,395,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Santori & Peters Inc. acquired a new stake in Merck & Co. during the 4th quarter valued at $110,000. Stevens First Principles Investment Advisors increased its holdings in Merck & Co. by 79.3% during the 4th quarter. Stevens First Principles Investment Advisors now owns 2,080 shares of the company’s stock valued at $117,000 after purchasing an additional 920 shares in the last quarter. Avestar Capital LLC acquired a new stake in Merck & Co. during the 4th quarter valued at $130,000. WealthTrust Arizona LLC increased its holdings in Merck & Co. by 103.7% during the 4th quarter. WealthTrust Arizona LLC now owns 2,495 shares of the company’s stock valued at $140,000 after purchasing an additional 1,270 shares in the last quarter. Finally, Taylor Hoffman Wealth Management acquired a new stake in Merck & Co. during the 4th quarter valued at $156,000. 74.87% of the stock is owned by institutional investors and hedge funds.

In other news, EVP Julie L. Gerberding sold 9,972 shares of the firm’s stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $59.66, for a total value of $594,929.52. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Weir Mirian M. Graddick sold 24,000 shares of the firm’s stock in a transaction on Monday, April 16th. The stock was sold at an average price of $58.00, for a total value of $1,392,000.00. The disclosure for this sale can be found here. 0.32% of the stock is currently owned by company insiders.

Shares of Merck & Co. opened at $59.14 on Monday, according to Marketbeat Ratings. The firm has a market capitalization of $159.45 billion, a price-to-earnings ratio of 14.86, a PEG ratio of 2.25 and a beta of 0.76. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.10 and a current ratio of 1.42. Merck & Co. has a 52 week low of $52.83 and a 52 week high of $66.41.

Merck & Co. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, May 1st. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $1.00 by $0.05. The firm had revenue of $10.04 billion for the quarter, compared to analyst estimates of $10.09 billion. Merck & Co. had a return on equity of 30.93% and a net margin of 4.31%. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same period last year, the company earned $0.88 EPS. analysts forecast that Merck & Co. will post 4.23 EPS for the current year.

A number of equities research analysts recently weighed in on the company. Jefferies Group set a $55.00 price target on Merck & Co. and gave the company a “hold” rating in a report on Friday, March 23rd. ValuEngine cut Merck & Co. from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. DZ Bank raised Merck & Co. from a “hold” rating to a “buy” rating in a report on Tuesday, February 13th. Morgan Stanley raised their price target on Merck & Co. from $60.00 to $63.00 and gave the company an “equal weight” rating in a report on Wednesday, February 7th. Finally, Credit Suisse Group dropped their price target on Merck & Co. from $67.00 to $66.00 and set an “outperform” rating for the company in a report on Monday, February 5th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $65.87.

Merck & Co. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply